Observational analysis reveals melatonin significantly improves cell viability and reduces apoptosis in 5-FU-treated H9c2 cells, indicating a potential therapeutic application.
Cardiotoxicity represents a significant adverse effect associated with 5-fluorouracil (5-FU), a widely used chemotherapeutic agent. Melatonin (MLT), a powerful antioxidant and agent that prevents apoptosis, has shown promise in mitigating various toxicities. This study evaluated the cardioprotective effect of MLT on 5-FU-induced cardiotoxicity (5-FU-IC) in the H9c2 cardiomyoblast cell line. The cells were grown in DMEM + FBS and divided into four groups: control (untreated), 5-FU-treated (varying concentrations for 48 hours), MLT-treated (varying concentrations), and 5-FU plus MLT-treated (combined treatment for 48 hours). The cell viability was evaluated using the MTT assay, while apoptosis was analyzed through flow cytometry following Annexin V staining and caspase-3/7 (Cas-3/7) activity assays. Treatment with 5-FU led to a significant decrease in the viability of H9c2 cells in a dose-dependent fashion, with an estimated IC50 value of 400 μM. Co-treatment with MLT at 100 and 200 μM significantly enhanced cell viability and reduced apoptosis induced by 5-FU, as demonstrated by flow Cytometry and reduced Cas-3/7 activity. These results emphasize the protective effects of MLT against 5-FU-IC, primarily through its anti-apoptotic mechanisms. These findings underscore the importance of MLT to protect against 5-FU-IC through its anti-apoptotic properties. MLT shows promise as a cardioprotective agent in mitigating 5-FU-IC, providing perspectives on its potential therapeutic application in mitigating cardiac risks linked to chemotherapy.
No takes yet. Share an insight, caveat, or question.
Ali Akbar Moghadamnia (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: